{"id":2345,"date":"2025-11-04T14:34:50","date_gmt":"2025-11-04T13:34:50","guid":{"rendered":"https:\/\/semmelweis.hu\/esk\/?p=2345"},"modified":"2025-12-05T14:35:39","modified_gmt":"2025-12-05T13:35:39","slug":"az-influenza-a-elleni-oltoanyagok-eredmenyessege-az-idosebb-nepesseg-koreben-kiegeszitve-a-kronikus-betegsegek-hatasanak-vizsgalataval","status":"publish","type":"post","link":"https:\/\/semmelweis.hu\/esk\/2025\/11\/04\/az-influenza-a-elleni-oltoanyagok-eredmenyessege-az-idosebb-nepesseg-koreben-kiegeszitve-a-kronikus-betegsegek-hatasanak-vizsgalataval\/","title":{"rendered":"Az influenza A elleni olt\u00f3anyagok eredm\u00e9nyess\u00e9ge az id\u0151sebb n\u00e9pess\u00e9g k\u00f6r\u00e9ben, kieg\u00e9sz\u00edtve a kr\u00f3nikus betegs\u00e9gek hat\u00e1s\u00e1nak vizsg\u00e1lat\u00e1val"},"content":{"rendered":"<h5 style=\"text-align: center\"><strong>Az I-MOVE* \u00e9s VEBIS** Eur\u00f3pai k\u00f3rh\u00e1zi vizsg\u00e1latok eredm\u00e9nye, 2015\/16 \u2013 2023\/24<\/strong><\/h5>\n<p style=\"text-align: justify\">Az I-MOVE\/I-MOVE+ \u00e9s a VEBIS k\u00f3rh\u00e1zi h\u00e1l\u00f3zatok r\u00e9szek\u00e9nt a 2015\/16. \u00f3ta v\u00e9gz\u00fcnk szezon\u00e1lis, t\u00f6bbk\u00f6zpont\u00fa, teszt-negat\u00edv eset-kontroll vizsg\u00e1latokat Eur\u00f3p\u00e1ban az influenza elleni v\u00e9d\u0151olt\u00e1s-eredm\u00e9nyess\u00e9g (IVE) \u00e9rt\u00e9kel\u00e9s\u00e9re. Jelen tanulm\u00e1nyunkban a 65 \u00e9ves \u00e9s id\u0151sebb feln\u0151ttek k\u00f6r\u00e9ben vizsg\u00e1ltuk a kr\u00f3nikus betegs\u00e9gek hat\u00e1s\u00e1t az influenza A alt\u00edpusai elleni v\u00e9d\u0151olt\u00e1s-eredm\u00e9nyess\u00e9gre, t\u00f6bb szezon (2015\/16\u20132023\/24) \u00f6sszes\u00edtett adatait felhaszn\u00e1lva.<\/p>\n<p style=\"text-align: justify\">A k\u00f3rh\u00e1zi vizsg\u00e1latban t\u00f6bb m\u00e1sik kutat\u00f3csoporttal egy\u00fctt azokt\u00f3l a betegekt\u0151l vett\u00fcnk orr- \u00e9s garatv\u00e1lad\u00e9k-mint\u00e1t, akikn\u00e9l a t\u00fcnetek megjelen\u00e9s\u00e9t k\u00f6vet\u0151 7 napon bel\u00fcl s\u00falyos akut l\u00e9g\u00fati megbeteged\u00e9s (SARI) alakult ki. Az influenzav\u00edrus A(H1N1)pdm09 vagy A(H3N2) t\u00edpusaira RT-PCR m\u00f3dszerrel pozit\u00edvnak bizonyult betegeket az esetek k\u00f6z\u00e9 soroltuk, m\u00edg azokat, akikn\u00e9l semmilyen influenzav\u00edrus nem volt kimutathat\u00f3, kontrollk\u00e9nt defini\u00e1ltuk. A teljes id\u0151szakra vonatkoz\u00f3 \u00f6sszes\u00edtett IVE-t az A(H1N1)pdm09 \u00e9s A(H3N2) alt\u00edpusok szerint sz\u00e1m\u00edtottuk ki, korrig\u00e1lva a vizsg\u00e1lati helysz\u00ednre, nemre, \u00e9letkorra \u00e9s a t\u00fcnetek kezdet\u00e9re. Az elemz\u00e9st a kr\u00f3nikus betegs\u00e9gek sz\u00e1ma \u00e9s t\u00edpusa szerint tov\u00e1bbi alcsoportokra bontottuk: cukorbetegek, sz\u00edv- \u00e9s \u00e9rrendszeri betegek \u2013 a magas v\u00e9rnyom\u00e1s kiv\u00e9tel\u00e9vel \u2013, t\u00fcd\u0151t \u00e9rint\u0151 kr\u00f3nikus betegs\u00e9gben vagy asztm\u00e1ban szenved\u0151k, immundefektusban szenved\u0151k, vesebetegek, m\u00e1jbetegek, rosszindulat\u00fa daganatos betegek, valamint elh\u00edzottak csoportj\u00e1ra. Az elemz\u00e9s r\u00e9szek\u00e9nt megvizsg\u00e1ltuk az oltotts\u00e1g \u00e9s az egyes kr\u00f3nikus betegs\u00e9gek k\u00f6z\u00f6tti \u00f6sszef\u00fcgg\u00e9seket is.<\/p>\n<p style=\"text-align: justify\">12 k\u00fcl\u00f6nb\u00f6z\u0151 orsz\u00e1gb\u00f3l (13 vizsg\u00e1lati helysz\u00edn) \u00f6sszesen 1805 A(H1N1)pdm09-esetet \u00e9s 16\u00a0329 kontrollt, valamint 2590 A(H3N2)-esetet \u00e9s 14\u00a0920 kontrollt vontunk be az elemz\u00e9sbe. Minden szezon adatait figyelembev\u00e9ve az esetek 63\u201367%-\u00e1nak, m\u00edg a kontrollok 70%-\u00e1nak legal\u00e1bb k\u00e9t kr\u00f3nikus alapbetegs\u00e9ge volt.<\/p>\n<p style=\"text-align: justify\">Az A(H1N1)pdm09 ellen az \u00f6sszes\u00edtett IVE 37% volt (95% CI: 29\u201344). A kr\u00f3nikus betegs\u00e9gek sz\u00e1m\u00e1t is figyelembev\u00e9ve:<\/p>\n<ul style=\"text-align: justify\">\n<li>0 betegs\u00e9g eset\u00e9n az IVE 49% (95% CI: 9\u201372),<\/li>\n<li>1 betegs\u00e9g eset\u00e9n az IVE 30% (95% CI: 12\u201344),<\/li>\n<li>\u00e9s \u22652 betegs\u00e9g eset\u00e9n az IVE 38% (95% CI: 29\u201346).<\/li>\n<\/ul>\n<p style=\"text-align: justify\">A becsl\u00e9sek szerint a legt\u00f6bb IVE-\u00e9rt\u00e9k 34\u201345% k\u00f6z\u00f6tt mozgott, kiv\u00e9ve az immundefektusban\u00a0szenved\u0151 (-7%), a vesebetegek (17%) \u00e9s a m\u00e1jbeteg (54%) csoportokat, b\u00e1r a 95%-os konfidenciaintervallumok ezekben a csoportokban \u00e1tfedtek. Er\u0151s statisztikai bizony\u00edt\u00e9k utal arra, hogy k\u00f6lcs\u00f6nhat\u00e1s \u00e1ll fenn az oltotts\u00e1g \u00e9s a vesebetegs\u00e9g (p=0,02), valamint az oltotts\u00e1g \u00e9s az immundefektus (p=0,01) k\u00f6z\u00f6tt.<\/p>\n<p style=\"text-align: justify\">Az A(H3N2) ellen az \u00f6sszes\u00edtett IVE 17% volt (95% CI: 8\u201325). A kr\u00f3nikus betegs\u00e9gek sz\u00e1m\u00e1t\u00f3l f\u00fcgg\u0151en:<\/p>\n<ul style=\"text-align: justify\">\n<li>0 betegs\u00e9g eset\u00e9n az IVE 15% (95% CI: \u201326\u201342),<\/li>\n<li>1 betegs\u00e9g eset\u00e9n az IVE 11% (95% CI: \u20138\u201327),<\/li>\n<li>\u00e9s \u22652 betegs\u00e9g eset\u00e9n az IVE 18% (95% CI: 7\u201328).<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Itt az IVE-becsl\u00e9sek \u00e9rt\u00e9kei 13\u201325% k\u00f6z\u00f6tt mozogtak, kiv\u00e9ve az immundefektusban\u00a0szenved\u0151 (5%), a vesebeteg (6%) \u00e9s a m\u00e1jbeteg (31%) csoportokat, ahol a 95%-os CI-k szint\u00e9n \u00e1tfedtek. Ezekn\u00e9l a becsl\u00e9sekn\u00e9l statisztikailag jelent\u0151s k\u00f6lcs\u00f6nhat\u00e1s nem volt megfigyelhet\u0151.<\/p>\n<p style=\"text-align: justify\">Az \u00f6sszes\u00edtett szezon\u00e1lis adatok eredm\u00e9nyei alapj\u00e1n az influenza A alt\u00edpusok elleni olt\u00e1sok hat\u00e1soss\u00e1ga az id\u0151sebb SARI-betegek k\u00f6r\u00e9ben alacsony vagy k\u00f6zepes m\u00e9rt\u00e9k\u0171, \u00e9s az influenza A(H1N1)pdm09 t\u00edpusa ellen magasabb, mint az A(H3N2) ellen. A kr\u00f3nikus betegs\u00e9gek t\u00f6bbs\u00e9ge csak m\u00e9rs\u00e9kelt hat\u00e1st gyakorolt az IVE-becsl\u00e9sekre, de a vesebetegs\u00e9g \u00e9s az immundefektus eset\u00e9ben ez jelent\u0151sebb volt.<\/p>\n<p style=\"text-align: justify\">Eredm\u00e9nyeink al\u00e1t\u00e1masztj\u00e1k az influenzaolt\u00e1sok c\u00e9lzottabb \u00e9s hat\u00e9konyabb fejleszt\u00e9s\u00e9nek sz\u00fcks\u00e9gess\u00e9g\u00e9t a k\u00fcl\u00f6nb\u00f6z\u0151 c\u00e9lcsoportok sz\u00e1m\u00e1ra. Az id\u0151sebb koroszt\u00e1lyban v\u00e9gzett j\u00f6v\u0151beni kutat\u00e1sok sor\u00e1n tov\u00e1bb\u00e1 c\u00e9lszer\u0171 lenne r\u00e9szletesen vizsg\u00e1lni a kr\u00f3nikus betegs\u00e9gek \u00e9s a v\u00e9d\u0151olt\u00e1s-eredm\u00e9nyess\u00e9g k\u00f6z\u00f6tti \u00f6sszef\u00fcgg\u00e9seket.<\/p>\n<ol>\n<li style=\"text-align: justify\"><span style=\"font-size: 14pt\"><strong>\u00e1<\/strong><strong>bra: Az influenza A elleni v\u00e9d\u0151olt\u00e1s-eredm\u00e9nyess\u00e9g az id\u0151s feln\u0151ttek k\u00f6r\u00e9ben a kr\u00f3nikus betegs\u00e9gek hat\u00e1s\u00e1nak elemz\u00e9s\u00e9vel: az I-MOVE \u00e9s VEBIS t\u00f6bbk\u00f6zpont\u00fa eur\u00f3pai k\u00f3rh\u00e1zi eset-kontroll vizsg\u00e1latainak eredm\u00e9nyei (2015\/16\u20132023\/24)<\/strong><\/span><\/li>\n<\/ol>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-2346 size-full\" src=\"https:\/\/semmelweis.hu\/esk\/files\/2025\/12\/Recenzio13_abravegleges.png\" alt=\"\" width=\"908\" height=\"746\" srcset=\"https:\/\/semmelweis.hu\/esk\/files\/2025\/12\/Recenzio13_abravegleges.png 908w, https:\/\/semmelweis.hu\/esk\/files\/2025\/12\/Recenzio13_abravegleges-400x329.png 400w, https:\/\/semmelweis.hu\/esk\/files\/2025\/12\/Recenzio13_abravegleges-768x631.png 768w, https:\/\/semmelweis.hu\/esk\/files\/2025\/12\/Recenzio13_abravegleges-753x619.png 753w\" sizes=\"auto, (max-width: 908px) 100vw, 908px\" \/><\/p>\n<p style=\"text-align: justify\"><span style=\"font-size: 12pt\">Az I-MOVE\/I-MOVE+ \u00e9s a VEBIS vizsg\u00e1latokban r\u00e9sztvev\u0151 helysz\u00ednek, 2015\/16 \u2013 2023\/24.<\/span><\/p>\n<p style=\"text-align: justify\"><span style=\"font-size: 12pt\">AL: Alb\u00e1nia; BE: Belgium; CZ: Csehorsz\u00e1g; DE: N\u00e9metorsz\u00e1g; ES: Spanyolorsz\u00e1g (Navarra tartom\u00e1ny kiv\u00e9tel\u00e9vel); FI: Finnorsz\u00e1g; FR: Franciaorsz\u00e1g; HR: Horv\u00e1torsz\u00e1g; HU: Magyarorsz\u00e1g; IE: \u00cdrorsz\u00e1g; I-MOVE: Influenza \u2013 Monitoring Vaccine Effectiveness; IT: Olaszorsz\u00e1g; LT: Litv\u00e1nia; MT: M\u00e1lta; NA: Spanyolorsz\u00e1g, Navarra tartom\u00e1ny; NL: Hollandia; PL: Lengyelorsz\u00e1g; PT: Portug\u00e1lia; RO: Rom\u00e1nia; SC: Sk\u00f3cia; VEBIS: Vaccine Effectiveness, Burden and Impact Studies<\/span><\/p>\n<p style=\"text-align: justify\"><span style=\"font-size: 12pt\">Forr\u00e1s: BMC Med. 2025 Nov 3;23:602. doi: 10.1186\/s12916-025-04426-y publik\u00e1ci\u00f3 1. \u00e1br\u00e1ja alapj\u00e1n SE ESK saj\u00e1t szerkeszt\u00e9s<\/p>\n<p><\/span><\/p>\n<h3 style=\"text-align: justify\"><strong>Vaccine effectiveness against influenza A in older adults and the effect of chronic conditions: results from the I-MOVE and VEBIS multicentre European hospital case\u2013control studies, 2015\/16\u20132023\/24<\/strong><\/h3>\n<p style=\"text-align: justify\"><em>Angela Mary Catherine Rose<\/em> (Epiconcept, P\u00e1rizs, Franciaorsz\u00e1g)<br \/>\n<em>Nathalie Nicolay <\/em>(European Centre for Disease Prevention and Control, Stockholm, Sv\u00e9dorsz\u00e1g)<br \/>\n<em>Beatrix Oroszi PhD\u00a0<\/em>(National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest)<br \/>\nand the I-MOVE &amp; VEBIS Hospital Network team<\/p>\n<h5 style=\"text-align: justify\"><strong>Abstract<\/strong><\/h5>\n<p style=\"text-align: justify\">Background:<\/p>\n<p style=\"text-align: justify\">The Influenza \u2013 Monitoring Vaccine Effectiveness in Europe (I-MOVE\/I-MOVE+) and Vaccine Effectiveness, Burden and Impact Studies (VEBIS) hospital networks have conducted seasonal multicentre, test-negative, case\u2013control studies in Europe to measure influenza vaccine effectiveness (IVE) since 2015\/16. We measured the effect of chronic conditions on VE of influenza A subtypes among older adults (\u2265\u200965 years) using pooled-season data (2015\/16\u20132023\/24).<\/p>\n<p style=\"text-align: justify\">Methods:<\/p>\n<p style=\"text-align: justify\">Hospital teams swabbed patients with severe acute respiratory infection (SARI) within 7 days of symptom onset. Cases were RT-PCR positive for influenza A(H1N1)pdm09 or A(H3N2); controls negative for any influenza virus. We calculated overall pooled-season IVE against influenza A(H1N1)pdm09 and A(H3N2), adjusted for study site, sex, age and onset date; and stratified by number of and by each chronic condition (diabetes, heart disease, lung disease\/asthma, immunosuppression, kidney disease, liver disease, cancer, obesity). We investigated interaction between vaccination and each condition.<\/p>\n<p style=\"text-align: justify\">Results:<\/p>\n<p style=\"text-align: justify\">We included 1805 A(H1N1)pdm09 cases with 16,329 controls; 2590 A(H3N2) cases with 14,920 controls, from 13 study sites (12 countries). Over all seasons, 63\u201367% cases and 70% controls had\u2009\u2265\u20092 chronic conditions.<\/p>\n<p style=\"text-align: justify\">Against A(H1N1)pdm09, pooled-season IVE was 37% (95%CI: 29\u201344) overall; 49% (95%CI: 9\u201372), 30% (95%CI: 12\u201344) and 38% (95%CI: 29\u201346) in those with 0, 1,\u2009\u2265\u20092 chronic conditions. Most IVE point estimates were 34\u201345%, apart from immunosuppression (-7%), kidney disease (17%) and liver disease (54%), but 95% CIs overlapped. Significant interaction was observed for kidney disease (p\u2009=\u20090.02) and immunosuppression (p\u2009=\u20090.01). Against A(H3N2), pooled-season IVE was 17% (95%CI: 8\u201325) overall; 15% (95%CI: -26\u201342), 11% (95%CI: -8\u201327) and 18% (95%CI: 7\u201328) in those with 0, 1,\u2009\u2265\u20092 chronic conditions. Here, IVE point estimates ranged 13\u201325%, apart from immunosuppression (5%), kidney disease (6%) and liver disease (31%), although 95% CIs overlapped. There were no significant interactions.<\/p>\n<p style=\"text-align: justify\">Conclusions:<\/p>\n<p style=\"text-align: justify\">Pooled-season results suggest low\u2013moderate VE against influenza A subtypes among older SARI patients; higher against A(H1N1)pdm09 than A(H3N2), with little evidence of chronic condition modifying effect, apart from kidney disease and immunosuppression. We stress the importance of developing improved influenza vaccines for specific populations, and encourage further research into the effect of chronic conditions on IVE in older adults.<\/p>\n<p style=\"text-align: justify\">\u00a0<\/p>\n<p style=\"text-align: justify\"><span style=\"font-size: 12pt\">* Influenza \u2013 Monitoring Vaccine Effectiveness in Europe<br \/>\n<\/span><span style=\"font-size: 12pt\">** Vaccine Effectiveness, Burden and Impact Studies<\/span><\/p>\n<p style=\"text-align: justify\"><span style=\"font-size: 12pt\">Rose AMC, Nicolay N, Mazagatos C, Mart\u00ednez-Baz I, Launay O, De Mot L, \u00e9s mtsai. Vaccine effectiveness against influenza A in older adults and the effect of chronic conditions: results from the I-MOVE and VEBIS multicentre European hospital case\u2013control studies, 2015\/16\u20132023\/24. BMC Medicine. 2025. november 3.;23(1):602. https:\/\/doi.org\/10.1186\/s12916-025-04426-y<\/span><\/p>\n<p style=\"text-align: justify\"><a href=\"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04426-y\" target=\"_blank\" rel=\"noopener\"><strong>https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04426-y<\/strong><\/a><\/p>\n<p><span style=\"font-size: 12pt;color: #003366\"><em>K\u00e9sz\u00edtette az <img loading=\"lazy\" decoding=\"async\" class=\"alignnone  wp-image-1068\" src=\"https:\/\/semmelweis.hu\/esk\/files\/2024\/02\/se_esk_logo_fekvo_sotet-400x90.png\" alt=\"\" width=\"263\" height=\"59\" srcset=\"https:\/\/semmelweis.hu\/esk\/files\/2024\/02\/se_esk_logo_fekvo_sotet-400x90.png 400w, https:\/\/semmelweis.hu\/esk\/files\/2024\/02\/se_esk_logo_fekvo_sotet-768x172.png 768w, https:\/\/semmelweis.hu\/esk\/files\/2024\/02\/se_esk_logo_fekvo_sotet-753x169.png 753w, https:\/\/semmelweis.hu\/esk\/files\/2024\/02\/se_esk_logo_fekvo_sotet.png 900w\" sizes=\"auto, (max-width: 263px) 100vw, 263px\" \/>\u00a0<\/em><\/span><\/p>\n<p><span style=\"font-size: 12pt\"><em><img loading=\"lazy\" decoding=\"async\" class=\"alignnone  wp-image-1662\" src=\"https:\/\/semmelweis.hu\/esk\/files\/2024\/10\/Nemzeti_Labor__logo-400x167.jpg\" alt=\"\" width=\"165\" height=\"69\" srcset=\"https:\/\/semmelweis.hu\/esk\/files\/2024\/10\/Nemzeti_Labor__logo-400x167.jpg 400w, https:\/\/semmelweis.hu\/esk\/files\/2024\/10\/Nemzeti_Labor__logo.jpg 710w\" sizes=\"auto, (max-width: 165px) 100vw, 165px\" \/><\/em><span style=\"color: #003366\">RRF-2.3.1-21-2022-00006\u00a0<\/span><\/span><\/p>\n<p><b><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-803 \" src=\"https:\/\/semmelweis.hu\/esk\/files\/2023\/11\/RRF-1024x118.jpg\" alt=\"\" width=\"788\" height=\"91\" srcset=\"https:\/\/semmelweis.hu\/esk\/files\/2023\/11\/RRF-1024x118.jpg 1024w, https:\/\/semmelweis.hu\/esk\/files\/2023\/11\/RRF-400x46.jpg 400w, https:\/\/semmelweis.hu\/esk\/files\/2023\/11\/RRF-768x88.jpg 768w, https:\/\/semmelweis.hu\/esk\/files\/2023\/11\/RRF-1536x177.jpg 1536w, https:\/\/semmelweis.hu\/esk\/files\/2023\/11\/RRF-2048x235.jpg 2048w, https:\/\/semmelweis.hu\/esk\/files\/2023\/11\/RRF-753x87.jpg 753w\" sizes=\"auto, (max-width: 788px) 100vw, 788px\" \/><\/b><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Az I-MOVE* \u00e9s VEBIS** Eur\u00f3pai k\u00f3rh\u00e1zi vizsg\u00e1latok eredm\u00e9nye, 2015\/16 \u2013 2023\/24 Az I-MOVE\/I-MOVE+ \u00e9s a VEBIS k\u00f3rh\u00e1zi h\u00e1l\u00f3zatok r\u00e9szek\u00e9nt a 2015\/16. \u00f3ta v\u00e9gz\u00fcnk szezon\u00e1lis, t\u00f6bbk\u00f6zpont\u00fa, teszt-negat\u00edv eset-kontroll vizsg\u00e1latokat Eur\u00f3p\u00e1ban az influenza elleni v\u00e9d\u0151olt\u00e1s-eredm\u00e9nyess\u00e9g (IVE) \u00e9rt\u00e9kel\u00e9s\u00e9re. Jelen tanulm\u00e1nyunkban a 65 \u00e9ves \u00e9s id\u0151sebb feln\u0151ttek k\u00f6r\u00e9ben vizsg\u00e1ltuk a kr\u00f3nikus betegs\u00e9gek hat\u00e1s\u00e1t az influenza A alt\u00edpusai elleni v\u00e9d\u0151olt\u00e1s-eredm\u00e9nyess\u00e9gre, &hellip;<\/p>\n","protected":false},"author":102284,"featured_media":2346,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[],"class_list":["post-2345","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cikk-osszefoglalok"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/2345","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/users\/102284"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/comments?post=2345"}],"version-history":[{"count":2,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/2345\/revisions"}],"predecessor-version":[{"id":2348,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/2345\/revisions\/2348"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/media\/2346"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/media?parent=2345"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/categories?post=2345"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/tags?post=2345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}